Sequential method for determining the half effective dose of propofol in obese patients with remazolam undergoing painless gastrointestinal endoscopy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053697

Enrollment

Unknown

Registered

2021-11-27

Start date

2021-11-30

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

intervention group:Drug concentration

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients who are going to undergo gastrointestinal endoscopy; 2. Aged 18 to 65 years, gender is not limited; 3. Body mass index (BMI) > 28kg/m^2; 4. The American Society of Anesthesiologists (ASA) is graded I to III.

Exclusion criteria

Exclusion criteria: 1. Patients who refuse to participate in the trial; 2. Those with a history of severe heart, brain, lung, liver, kidney and metabolic diseases; 3. There is a history of acute inflammation of the respiratory tract and no cure within 2 weeks; 4. Systolic blood pressure > 180 mm Hg and (or) diastolic blood pressure > 110 mm Hg in patients with preoperative hypertension, or < 90/60 mm Hg in patients with hypotension; 5. Those with neuromuscular disease and mental disease; 6. Asthma attack period; 7. Gastrointestinal obstruction with retention of gastric contents; 8. Suspected abuse of narcotic analgesics or sedatives; 9. Those who do not cooperate and cannot communicate.

Design outcomes

Primary

Measure	Time frame
blood pressure;Heart rate;	—

Countries

China

Contacts

Public ContactYuan Ruimei

Jinan Central Hospital

subave@sina.cn+86 15554127179

Outcome results